Good afternoon, ladies and gentlemen, and welcome to Huron Consulting Group's webcast to discuss financial results for the second quarter 2018. [Operator Instructions] As a reminder, this conference call is being recorded. Before we begin, I would like to point all of you to the disclosure at the end of the company's news release for information about any forward-looking statements that may be made or discussed on this call. The news release is posted on Huron's website. Please review that information along with the filings with the SEC for a disclosure of factors that may impact subjects discussed in this afternoon's webcast. The company will be discussing one or more non-GAAP financial measures. Please look at the earnings release and on Huron's website for all disclosures required by the SEC, including reconciliation to the most comparable GAAP numbers. And now I would like to turn the call over to Jim Roth, Chief Executive Officer and President of Huron Consulting Group. Mr. Roth, please go ahead.

Good afternoon, and welcome to Huron Consulting Group's Second Quarter 2018 Earnings Call. With me today is John Kelly, our Chief Financial Officer; and Mark Hussey, our Chief Operating Officer. Revenues grew 9% over the prior year quarter and 2% sequentially driven by organic growth in each of our three operating segments. Our second quarter performance reflects solid demand for our services, and we remain encouraged about our prospects for continued growth during the remainder of 2018. Although we are still in the early days of our multiyear organic growth strategy, I am pleased to report signs of progress this quarter. As I previously shared with you, we believe that the strategic actions we are taking to facilitate organic growth will improve shareholder value as our transformational efforts gain further traction. I will now provide a brief overview of the performance for each segment and then John will add color to the financials. Let me begin with Healthcare. During the second quarter, Healthcare segment revenues increased 10% organically compared to the prior year quarter. The quarter-over-quarter increase in revenues was primarily attributable to our performance improvement and technology services solutions. Over the past year, our Healthcare team, under Mark Hussey's leadership, has developed new delivery models that are more responsive to the evolving health care marketplace. We have also unified our go-to-market strategy and made an investment in sales, operations and support to drive increased productivity and efficiency in our selling model as we accommodate a larger number of smaller, more discrete engagements. We also expanded the breadth of our offerings within the Healthcare business and collaboration across other Huron businesses. As our second quarter results indicate, we believe success from these efforts is beginning to come to fruition. Conditions remain favorable for continued growth in the health care market.…

Thank you, Jim, and good afternoon, everyone. Before I begin, please note that I will be discussing non-GAAP financial measures such as EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS and free cash flow. Our press release, 10-Q and Investor Relations page on the Huron website have reconciliations of these non-GAAP measures to the most comparable GAAP measures along with a discussion of why management uses these non-GAAP measures and why management believes they provide useful information to investors regarding our financial condition and operating results. Also, unless otherwise stated, my comments today are all on a continuing operations basis. Now let me walk you through some of the key financial results for the quarter. Revenues for the second quarter of 2018 increased 8.9% to $197.5 million compared to $181.4 million in the same quarter of 2017. The increase in revenues in the quarter was driven by organic growth across all three segments. Net income was $5.9 million or $0.27 per diluted share in the second quarter of 2018 compared to net loss of $150.5 million or $7 per diluted share in the same quarter last year. The net loss was primarily attributable to the $210 million noncash pretax goodwill impairment charge recorded in the second quarter of 2017 related to our Healthcare segment. Our effective income tax rate in the second quarter of 2018 was 30.4% compared to 26.2% a year ago. Our effective tax rate for Q2 of this year was higher than the statutory rate inclusive of state income taxes due to nondeductible business expenses. Adjusted EBITDA was $24.7 million in Q2 2018 or 12.5% of revenues compared to $24.5 million in Q2 2017 or 13.5% of revenues. Adjusted non-GAAP net income was $12.8 million or $0.58 per diluted share in the second quarter of 2018 compared…

[Operator Instructions] The first question comes from Tim McHugh of William Blair. Your line is open.

Could you just, I guess, maybe talk a little bit more about the expenses? And I know you talked about some decisions you made or I guess, areas you invested in. But I guess just coming off the first quarter where expenses were a lot higher than expected and I think you kind of said it was consistent with what you expected at that time. So did opportunities come up throughout the quarter? I guess, walk us through maybe the thought process on spending levels at this point and the pace at which you're making investments?

Sure, Tim. This is John. I'll start. As the year has progressed and the business evolved and as we've started to execute on our organic growth strategy, these investments do represent incremental expenses that we believe are driving current and future growth and are ultimately going to add value and contribute to margin expansion over time. Just some examples within Healthcare, we're making investments in sales resources and client assessments. Within Education, we're investing in cloud resources and related training. And then within the Business Advisory segment, we've invested in Healthcare M&A resources as well as supporting infrastructure for our ES&A team. So I believe that all these items are going to lead to revenue growth and that our margins are going to expand over time.

I guess maybe just a follow-up, can you, I guess, quantify the size of all those? I think a little bit probably just given the magnitude of the revenue strength, surprising that you can't fund it with that amount of revenue?

In total, we estimate these items are approximately a 50 basis point headwind to our full year EBITDA margin. I'll also note that we incurred modest operating loss in the Middle East during the first four months of the year prior to our sale of this business. That was probably about a 20 basis point headwind on the first half. So we don't expect to incur any more losses related to the Middle East at this point.

And then just on that one, what's the drag to revenue now as you sold that business in the second quarter?

It's very minimal, Tim. The entire revenue for the first 6 months was very low single digit million dollars.

Our next question comes from the line of Tobey Sommer of SunTrust. You may proceed.

This is Kwan Kim on for Tobey. First, could you talk about the $7 million litigation item on the income statement for the quarter?

Yes. There's really two components within that item that get adjusted out. We had a $2.5 million gain related to the settlement of a legal case during the quarter. We collected the cash during the quarter. And then we had an adjustment to the fair value of our earn-out liability for another $4 million. And those two items together total probably that $7 million that you're looking at. Now as it relates to the earn-out's fair value exercise, we do that every quarter. And that's probably something that we expect to be volatile over time. It's likely that, that may go up or down as we progress through the year.

And on the use of cash, is debt reduction still the most likely use of cash over the next four quarters. So that you're targeting below 3.0?

It is, Kwan. I would say that definitely remains the priority certainly through the back half of the year. We expect to be below 3x by the end of the year. We'll have our bonus payouts during the first quarter next year so you'll likely see an increase in borrowings during that quarter, but then we expect to get below 3x again shortly thereafter.

Okay. And on the Education margin, that's down year-over-year, you said that's a result of higher salary. Are bonuses part of that increase in expenses or is it just purely salary?

That salary comment really relates to the increase in headcount year-over-year. We've had a significant increase in headcount as we build for organic growth. I'd say the primary driver of the decrease in bill rates and then that impacted margins for the quarter was we did have several large projects when we made some resource investments during the quarter to ensure success for our clients on those projects. And we think that's going to be a good foundation for those types of projects for us in the future. And we don't necessarily expect those items to repeat going forward.

Okay. And lastly, is the 7% year-over-year consultant headcount growth in the second quarter a good proxy for your annual plans or will the summer hiring season change the rate of growth?

I'd say from a headcount growth perspective, I think that's a good proxy, generally speaking.

Our next question comes from Bill Sutherland of Benchmark.

Jim Roth, can you talk a little bit about the breadth that you're increasing in the Healthcare capabilities beyond your bread-and-butter?

Yes. So I'm going to actually let Mark handle most of that, but just as a reminder, it wasn't that long ago that a majority of our work, our capabilities in that business were really strictly around performance improvement and revenue cycle. And even though those are still very prominent parts of our business, the team in the last couple of years has dramatically changed the business through a very significant transformation. Mark is probably the best one to talk about that. Mark, you want to handle that part of it?

Sure. Bill, so the way I would describe what we've done in Healthcare is really bring this whole notion of flexible delivery models to, based on really the client's concept of the problems they're trying to solve. And within really four pillars of how we go to market, we have strategy, innovation, which largely has been Innosight and very successful on that side. Our leadership component in patient experience, which is around Studer Group, technology services, which is around our EHR services and then our traditional performance improvement, which is revenue cycle and cost and clinical. In each of those areas, what I would characterize is that the ability to really unlock value by bringing them together in different ways to differentiate has been one element of success. And then I think just in general, having a much more flexible focus to the market, which is often leading to perhaps a little bit smaller engagement sizes, which is perfectly fine, but then it also sets the stage for follow-on work as well. So it's actually gone pretty well. And then outside of the Healthcare practice, we continue to focus on the other businesses that sell into Healthcare. Jim mentioned the M&A capability in the broker-dealer in Healthcare. That continues to be a bright spot early on in the evolution of that. And then our ES&A practice, which actually has worked a lot on more of the advanced analytics and those kinds of technical applications, those are also being brought into Healthcare on a collaborative basis.

Specifically on Studer, are they doing better quarter-over-quarter? Is this just a year-over-year issue in the second quarter?

Yes. From revenue perspective, Bill, I'd say sequentially, they did do a little bit better Q2 versus Q1. I'd say they're still performing during the year in line with what our expectations for the full year was, really no change there from a financial perspective. And to your point, it is just a year-over-year headwind related to some of the cancellations that we talked about a year ago.

Go ahead, Bill.

I was just going to say, so the cancel rate there has kind of normalized for Studer?

Yes. So let me add some color to John's comment. Things have stabilized dramatically. I think when we described this a year ago, it was some of the more large national systems that were doing some in-sourcing and the like. And we largely worked through the impact of that, but what we're doing with Studer Group in many respects, they have this, as the market is shifting and just like we're talking about flexible delivery models in some of the other areas of the business, within Studer really is very much the same concept. And that is starting to take hold and accelerate. And really as we look at where this business is going, really not only within the acute market, but really outside of just the pure acute market as well, in the pre-acute as well as post-acute settings. We think we've got, continue to have very attractive opportunities for this business.

And then just the last one. Kind of curious how much impact the pressures that are emerging across the, particularly the hospital sector relative to the reimbursement side and the cost side and then just competitive issues in general. Is this leading to more inquiries or are they kind of like a little frozen in place at the moment? I'm kind of curious kind of the status of the market.

No. I think the pipeline is good. I would say the market uncertainties are playing in a way that's been favorable for the business, for our business. I think there's continuing pressure on reimbursements. There's rising costs. You look at the amount of staffing labor that's going into the health care market at higher costs. There's a shortage of nursing. I mean, there's all kinds of just structural issues right now that, I think, are driving the needs for our services. And right now I don't see that there's any global solution that's going to change that in the short term. So I would say our clients are taking a very comprehensive and broad view of their businesses, and that's leading to opportunities in technology, in leadership, in performance improvement as well as strategy.

Mr. Roth, we have concluded the allotted time for this call. I'd like to turn the conference back over to you.

Thank you for spending time with us this afternoon. We look forward to speaking with you again in October when we announce our third quarter results. Have a good evening.

That concludes today's conference call. Thank you, everyone, for your participation.